Effect of excess body weight on the genetic susceptibility to cancer

Journal of Clinical Gastroenterology

Volumn 48, Issue , 2014, Pages S78-S79

  Burza, Maria A ^a   Spagnuolo, Rocco ^b   Montalcini, Tiziana ^b   Doldo, Patrizia ^b   Pujia, Arturo ^b   Romeo, Stefano ^a,b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Cancer; Genetic susceptibility; Insulin resistance; IRS1; Obesity

Indexed keywords

CANCER SUSCEPTIBILITY; CONFERENCE PAPER; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PROSTATE CANCER; RISK FACTOR; BODY WEIGHT; COMPLICATION; GENETIC PREDISPOSITION; GENETICS; GENOTYPE ENVIRONMENT INTERACTION; NEOPLASMS; PATHOPHYSIOLOGY;

BODY WEIGHT; GENE-ENVIRONMENT INTERACTION; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; NEOPLASMS; OBESITY; RISK FACTORS;

EID: 84916618436     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0000000000000237     Document Type: Conference Paper

References (21)

1. Finucane MM, Stevens GA, Cowan MJ, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet. 2011;377:557-567.
2. Flegal KM, Carroll MD, Kit BK, et al. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA. 2012;307:491-497.
3. Kopelman PG. Obesity as a medical problem. Nature. 2000; 404:635-643.
4. Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med. 2003;348: 1625-1638.
5. Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer: a systematic review and metaanalysis of prospective observational studies. Lancet. 2008; 371:569-578.
6. Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer. 2004;4:665-676.
7. Timofeeva MN, Hung RJ, Rafnar T, et al. Influence of common genetic variation on lung cancer risk: meta-analysis of 14900 cases and 29485 controls. Hum Mol Genet. 2012;21: 4980-4995.
8. Figueroa JD, Ye Y, Siddiq A, et al. Genome-wide association study identifies multiple loci associated with bladder cancer risk. Hum Mol Genet. 2014;23:1387-1398.
9. Taioli E, Garza MA, Ahn YO, et al. Meta- and pooled analyses of the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and colorectal cancer: a HuGE-GSEC review. Am J Epidemiol. 2009;170:1207-1221.
10. Frasca F, Pandini G, Sciacca L, et al. The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch Physiol Biochem. 2008;114:23-37.
11. Rung J, Cauchi S, Albrechtsen A, et al. Genetic variant near IRS1 is associated with type 2 diabetes, insulin resistance and hyperinsulinemia. Nat Genet. 2009;41:1110-1115.
12. Maglio C, Ericson U, Burza MA, et al. The IRS1 rs2943641 variant and risk of future cancer among morbidly obese individuals. J Clin Endocrinol Metab. 2013;98:E785-E789.
13. Corradini SG, Burza MA, Molinaro A, et al. Patatin-like phospholipase domain containing 3 sequence variant and hepatocellular carcinoma. Hepatology. 2011;53:1776.
14. Romeo S, Huang-Doran I, Baroni MG, et al. Unravelling the pathogenesis of fatty liver disease: patatin-like phospholipase domain-containing 3 protein. Curr Opin Lipidol. 2010;21: 247-252.
15. Dongiovanni P, Donati B, Fares R, et al. PNPLA3 I148M polymorphism and progressive liver disease. World J Gastroenterol. 2013;19:6969-6978.
16. Pirazzi C, Adiels M, Burza MA, et al. Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro. J Hepatol. 2012;57:1276-1282.
17. Huang Y, Cohen JC, Hobbs HH. Expression and characterization of a PNPLA3 protein isoform (I148M) associated with nonalcoholic fatty liver disease. J Biol Chem. 2011;286: 37085-37093.
18. Pingitore P, Pirazzi C, Mancina RM, et al. Recombinant PNPLA3 protein shows triglyceride hydrolase activity and its I148M mutation results in loss of function. Biochim Biophys Acta. 2014;1841:574-580.
19. Burza MA, Pirazzi C, Maglio C, et al. PNPLA3 I148M (rs738409) genetic variant is associated with hepatocellular carcinoma in obese individuals. Dig Liver Dis. 2012;44: 1037-1041.
20. Shu X, Lin J, Wood CG, et al. Energy balance, polymorphisms in the mTOR pathway, and renal cell carcinoma risk. J Natl Cancer Inst. 2013;105:424-432.
21. Mucci LA, Stark JR, Figg WD, et al. Polymorphism in endostatin, an angiogenesis inhibitor, and prostate cancer risk and survival: a prospective study. Int J Cancer. 2009;125: 1143-1146.